

Receipt date: 10/09/2008

Docket No.: RLL-509US

10549890 - GAU: 1626  
Serial No.: 10/549,899

# INFORMATION DISCLOSURE CITATION

Applicants: KUMAR *et al.*

Filed: 11/19/2004 (IA)

Group: ~~Unknown~~ 1626



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/J.N./	A1	5,003,080	3/26/1991	Butler <i>et al.</i>	548	517	
/J.N./	A2	5,097,045	3/17/1992	Butler <i>et al.</i>	549	373	
/J.N./	A3	5,103,024	4/7/1992	Millar <i>et al.</i>	549	373	
/J.N./	A4	5,124,482	6/23/1992	Butler <i>et al.</i>	564	169	
/J.N./	A5	5,149,837	9/22/1992	Butler <i>et al.</i>	549	333	
/J.N./	A6	5,155,251	10/13/1992	Butler <i>et al.</i>	558	442	
/J.N./	A7	5,216,174	6/1/1993	Butler <i>et al.</i>	548	517	
/J.N./	A8	5,245,047	9/14/1993	Butler <i>et al.</i>	548	517	
/J.N./	A9	5,248,793	9/28/1993	Millar <i>et al.</i>	549	375	
/J.N./	A10	5,273,995	12/28/1993	Roth	514	422	
/J.N./	A11	5,280,126	1/18/1994	Butler <i>et al.</i>	548	517	
/J.N./	A12	5,342,952	8/30/1994	Butler <i>et al.</i>	546	245	
/J.N./	A13	5,397,792	3/14/1995	Butler <i>et al.</i>	514	326	
/J.N./	A14	6,528,660	3/4/2003	Kumar <i>et al.</i>	548	537	
/J.N./	A15	6,613,916	9/2/2003	Pflaum	548	537	
/J.N./	A16	6,646,133	11/11/2003	Greff <i>et al.</i>	548	537	
/J.N./	A17	2002/0183378	12/5/2002	Aronhime <i>et al.</i>	514	423	
/J.N./	A18	2003/0109569	6/12/2003	Sorsak	514	423	
/J.N./	A19	2004/0077708	4/22/2004	Grahek <i>et al.</i>	514	423	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO	
/J.N./	B1	EP 1 148 049	10/24/2001	EPO	C07D	207/34		
/J.N./	B2	WO 97/03960	2/6/1997	PCT	C07D	207/34		
/J.N./	B3	WO 00/71116	11/30/2000	PCT	A61K	31/40		

EXAMINER /Jason Nolan/

DATE CONSIDERED 10/01/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Receipt date: 10/09/2008

Docket No.: RLL-509US

10549890 - GAU: 1626

Serial No.: 10/549,899

**INFORMATION DISCLOSURE CITATION**Applicants: KUMAR *et al.*

Filed: 11/19/2004 (IA)

Group: ~~Unknown~~ 1626

/J.N./	B4	WO 01/28999	4/26/2001	PCT	C07D	207/34		
/J.N./	B5	WO 01/42209	6/14/2001	PCT	C07D	207/34		
/J.N./	B6	WO 02/41834	5/30/2002	PCT	A61K			
/J.N./	B7	WO 02/051804	7/4/2002	PCT	C07D	207/34		
/J.N./	B8	WO 02/057228	7/25/2002	PCT	C07D	207/34		
/J.N./	B9	WO 02/083637	10/24/2002	PCT	C07D	207/34		
/J.N./	B10	WO 02/083638	10/24/2002	PCT	C07D	207/34		
/J.N./	B11	WO 03/004470	1/16/2003	PCT	C07D	207/34		
/J.N./	B12	WO 03/011826	2/13/2003	PCT	C07D	207/34		
/J.N./	B13	WO 03/018547	3/6/2003	PCT	C07D			
/J.N./	B14	WO 03/068739	8/21/2003	PCT	C07D	207/34		
/J.N./	B15	WO 03/078379	9/25/2003	PCT	C07C	69/732		
/J.N./	B16	WO 03/099785	12/4/2003	PCT	C07D	207/34		
/J.N./	B17	WO 2004/085391	10/7/2004	PCT	C07D	207/34		

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

/J.N./	C1	Brower et al, "The Synthesis of (4R-cis)-1,1-Dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate, a Key Intermediate for the Preparation of CI-981, a Highly Potent, Tissue Selective Inhibitor of HMG-CoA Reductase", <i>Tetrahedron Letters</i> , <u>33</u> (17):2279-2282 (1992)
/J.N./	C2	Shimako et al, "Atorvastatin (CI-981) Clinical Pharmacokinetic Study (I): Relative Bioavailability of Amorphous and Crystalline Preparations of Atorvastatin", <i>Japanese Pharmacology and Therapeutics</i> , <u>26</u> (8):1241-1252 (1998)
/J.N./	C3	Wade et al., "In Pursuit of Higher Purity: Use of <sup>13</sup> C NMR and <sup>13</sup> C-Enriched Substrates To Trace Impurity Generation and Removal in the Synthesis of Atorvastatin", <i>Organic Process Research and Development</i> , <u>1</u> (4):320-324 (1997)

EXAMINER /Jason Nolan/

DATE CONSIDERED

10/01/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.